Enzyme replacement therapy represents 56.4% of therapy type sales and hospitals account for 53.0% within the end user segment in 2026. The mucopolysaccharidosis treatment market is estimated at USD 3.0 billion in 2026, is projected to reach USD 5.3 billion by 2036 and is forecast to post a 5.9% CAGR between 2026 and 2036.